Poseida Therapeutics, Inc. (PSTX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biotech company tackles cancer, autoimmune disorders, and rare diseases all at once? Poseida Therapeutics, Inc. (PSTX) is making waves with its innovative approach to cell and gene therapies, but how exactly does it operate and generate revenue? Dive in to discover Poseida's history, mission, and the groundbreaking science behind its therapies, which has led to a 2024 stock price range of $1.05 - $4.25, and a current stock price of $9.50 as of April 2025.

Poseida Therapeutics, Inc. (PSTX) History

Founding Timeline

Year established

The company was established in 2014.

Original location

The company is headquartered in San Diego, California.

Founding team members

The founding team included:

• Eric Ostertag, MD, PhD (Chief Executive Officer)

Initial capital/funding

In 2015, the company completed a Series A financing round, raising $30 million.

Evolution Milestones

Transformative Moments

• Strategic Collaboration with Janssen: The partnership with Janssen Biotech in 2018 was a transformative moment, providing substantial financial resources and credibility to the company's CAR-T therapy programs. This collaboration validated the potential of the company's platform and accelerated the development of novel treatments for multiple myeloma.
• Initial Public Offering (IPO): The IPO in 2020 marked a significant milestone, providing the company with approximately $200 million in capital to advance its clinical programs and technology development. This event increased the company's visibility and access to capital markets, supporting long-term growth and innovation.
• Advancement of Allogeneic CAR-T Therapy: The clinical development of P-ALLO-1, an allogeneic CAR-T therapy, represents a transformative step towards off-the-shelf cell therapies. This program has the potential to broaden access to CAR-T therapy and overcome limitations associated with autologous approaches.

To gain more insights into the company's guiding principles, check out: Mission Statement, Vision, & Core Values of Poseida Therapeutics, Inc. (PSTX).

Poseida Therapeutics, Inc. (PSTX) Ownership Structure

Understanding the ownership structure of Poseida Therapeutics, Inc. is crucial for investors looking to grasp the company's control dynamics and potential influences on its strategic decisions. The following sections break down the company's current status, ownership distribution, and key leadership figures as of April 2025.

Poseida Therapeutics, Inc. Current Status

Poseida Therapeutics, Inc. is a publicly traded company, meaning its shares are available for purchase on a stock exchange. This allows a wide range of investors, from individuals to large institutions, to own a portion of the company. As a publicly traded entity, it is subject to regulatory oversight and reporting requirements, ensuring a level of transparency in its operations and financial performance. You can find more about the company's financial health here: Breaking Down Poseida Therapeutics, Inc. (PSTX) Financial Health: Key Insights for Investors

Poseida Therapeutics, Inc. Ownership Breakdown

The ownership of Poseida Therapeutics is distributed among various shareholders, including institutional investors, individual shareholders, and potentially company insiders. The following table provides an overview of the ownership breakdown.

Poseida Therapeutics, Inc. Leadership

The leadership team at Poseida Therapeutics plays a vital role in guiding the company's strategic direction and operational execution. Key members of the leadership team include:

• Kristin Yarema, Ph.D., President and Chief Executive Officer
• Mark J. Gergen, Chief Business Officer
• Yehoshua Shachar, M.D., Chief Medical Officer

These individuals, along with other members of the executive team, are responsible for making critical decisions about the company's research and development efforts, business development activities, and overall corporate strategy.

Poseida Therapeutics, Inc. (PSTX) Mission and Values

The company is dedicated to developing cell and gene therapies with the potential to cure cancer and rare diseases. Its core values emphasize innovation, collaboration, and a patient-centric approach to drive advancements in the field of biotechnology.

Poseida Therapeutics, Inc.'s Core Purpose

Official mission statement

Poseida Therapeutics' mission statement is:

• To translate best-in-class technologies into life-saving cell and gene therapies that achieve durable remission in patients with high unmet medical need.

This mission is reflected in their approach to developing novel therapies for both cancer and rare diseases. Poseida Therapeutics focuses on:

• Innovation: Pioneering new technologies to improve therapeutic outcomes.
• Patient-Centricity: Prioritizing the needs and well-being of patients in every aspect of their work.
• Collaboration: Working with partners to accelerate the development and delivery of life-saving therapies.

Vision statement

While a specific, formally declared vision statement isn't available in the provided search results, Poseida Therapeutics' vision can be inferred from their activities and goals:

• To be a leader in the development of cell and gene therapies, setting new standards for efficacy and safety.
• To create a future where serious diseases are effectively treated with innovative and accessible therapies.
• To transform the lives of patients and their families by providing hope and cures where none previously existed.

Company slogan/tagline

Information about the company's official slogan/tagline is not available in the search results. For detailed insights into Poseida Therapeutics, Inc.'s financial well-being, see Breaking Down Poseida Therapeutics, Inc. (PSTX) Financial Health: Key Insights for Investors.

Poseida Therapeutics, Inc. (PSTX) How It Works

Poseida Therapeutics, Inc. focuses on developing cell and gene therapies with the potential to cure patients with high unmet medical needs, utilizing proprietary genetic engineering platform technologies.

Poseida Therapeutics, Inc.'s Product/Service Portfolio

Poseida Therapeutics, Inc.'s Operational Framework

Poseida Therapeutics, Inc. operates with a focus on innovation in cell and gene therapies. Their operational framework includes several key aspects:

• Platform Technologies: Utilizing proprietary platforms like PiggyBac® DNA Modification System, Cas-CLOVER™ Site-Specific Gene Editing System, and biodegradable DNA and RNA delivery system.
• Allogeneic Approach: Developing allogeneic CAR-T cell therapies, using cells from healthy donors, which can be manufactured in advance and readily available for patients. This contrasts with autologous therapies that use a patient's own cells.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their product candidates. These trials are essential for regulatory approvals and demonstrating clinical benefit.
• Manufacturing: Establishing scalable manufacturing processes to produce CAR-T cell therapies. This includes both in-house capabilities and partnerships with contract manufacturing organizations (CMOs).
• Partnerships: Collaborating with other companies and academic institutions to advance research and development efforts.

Poseida Therapeutics, Inc.'s Strategic Advantages

Poseida Therapeutics, Inc. has several strategic advantages that enable its market success:

• Proprietary Technology: The PiggyBac® and Cas-CLOVER™ technologies provide a competitive edge in genetic engineering, allowing for precise and efficient gene editing and delivery.
• Allogeneic CAR-T Platform: Developing allogeneic CAR-T therapies offers significant advantages over autologous therapies, including reduced costs, faster treatment timelines, and broader patient access.
• Focus on Unmet Needs: Targeting cancers with high unmet medical needs, such as relapsed/refractory multiple myeloma and advanced solid tumors, allows Poseida to address critical gaps in treatment options.
• Experienced Management Team: A leadership team with expertise in cell and gene therapy development, manufacturing, and commercialization drives the company's strategic direction and operational execution.
• Strong Intellectual Property: A robust patent portfolio protects Poseida's proprietary technologies and product candidates, providing a barrier to entry for competitors.

To gain more insights into the company's financial standing, check out this link: Breaking Down Poseida Therapeutics, Inc. (PSTX) Financial Health: Key Insights for Investors

Poseida Therapeutics, Inc. (PSTX) How It Makes Money

Poseida Therapeutics, Inc. generates revenue primarily through strategic collaborations and licensing agreements focused on the research, development, and commercialization of its gene therapy and cell therapy platforms.

Poseida Therapeutics, Inc.'s Revenue Breakdown

As of the fiscal year 2024, the revenue streams can be categorized as follows:

Poseida Therapeutics, Inc.'s Business Economics

Poseida Therapeutics, Inc. operates in the competitive field of biopharmaceutical companies, emphasizing innovative therapies for cancer and genetic diseases. The company's economic model is characterized by:

• High R&D Investment: A significant portion of its expenditure is allocated to research and development to advance its pipeline of novel therapies.
• Strategic Collaborations: Collaborations with major pharmaceutical companies provide substantial upfront payments, milestone payments, and royalties on future sales, bolstering its financial position.
• Intellectual Property: Strong patent protection is crucial for maintaining a competitive edge and securing long-term revenue streams.

Poseida Therapeutics, Inc.'s Financial Performance

Key aspects of Poseida Therapeutics, Inc.'s financial performance include:

• Cash Reserves: As of the latest reports in 2024, the company maintains a healthy cash balance to fund ongoing research and clinical trials.
• Operating Expenses: The company experiences substantial operating expenses, primarily driven by R&D activities and clinical trial costs.
• Revenue Recognition: Revenue is recognized based on the achievement of milestones and the progression of collaborative projects.
• Net Losses: As is typical for many biotechnology companies in the development phase, Poseida Therapeutics, Inc. has historically reported net losses.

For more detailed insights into Poseida Therapeutics, Inc.'s financial health, you can explore this analysis: Breaking Down Poseida Therapeutics, Inc. (PSTX) Financial Health: Key Insights for Investors

Poseida Therapeutics, Inc. (PSTX) Market Position & Future Outlook

Poseida Therapeutics is navigating the competitive landscape of cell and gene therapy with a focus on developing innovative treatments for cancer and other diseases. The company's future outlook depends on the success of its clinical trials, strategic partnerships, and ability to secure funding in a dynamic biotech market. For an in-depth look at the company's financial standing, see Breaking Down Poseida Therapeutics, Inc. (PSTX) Financial Health: Key Insights for Investors.

Competitive Landscape

Opportunities & Challenges

Industry Position

Poseida Therapeutics holds a position as an innovative player within the competitive cell and gene therapy market. Key aspects of its industry standing include:

• Technology Platform: The company's proprietary gene engineering platforms, such as piggyBac® and Cas-CLOVER™, provide a competitive edge in developing differentiated cell and gene therapies.
• Clinical Pipeline: Poseida's pipeline includes several promising CAR-T and gene therapy candidates in various stages of clinical development, targeting hematologic malignancies and solid tumors.
• Allogeneic Approach: Focus on allogeneic CAR-T therapies (off-the-shelf) addresses limitations of autologous therapies (patient-specific), offering potential for broader accessibility and scalability.
• Financial Resources: The company's ability to secure funding through public offerings, partnerships, and collaborations is crucial for advancing its pipeline and achieving long-term success. As of the fiscal year 2024, Poseida Therapeutics reported total assets of $179.7 million, including $106.8 million in cash, cash equivalents, and marketable securities.